Introduction {#sec1-1753425918808008}
============

Pick up any book of animal or human pathology and you will invariably find a section devoted to the generalized Shwartzman reaction or phenomenon. The phenomenon connotes a hypersensitive innate immune response accompanied by an acute small vessel vasculopathy in association with diffuse intravascular coagulopathy (DIC).^1^ Pathologists will immediately recognize the characteristic histopathologic features and predict the likely clinical outcome. A rapidly fatal septic shock syndrome with scattered dermal necrosis will develop from *purpura fulminans* following bloodstream infection by *Neisseria meningitidis.* Yet, the term "Shwartzman phenomenon" seems to have fallen out of common parlance over the years, even among clinicians who take care of such patients. Does this nearly century-old observation have any residual relevance in modern medicine? Perhaps it is the current distaste for the use of eponyms in medical education or that the term has simply been subsumed by other broad categories such as systemic inflammatory states, disseminated intra vascular coagulation (DIC), septic shock, *purpura fulminans*, etc.

We will argue herein that the term has a rather specialized and unique meaning that is worth preserving. Endotoxin sensitization events followed by a provocative second event (the "two hit" model) still occurs in a subset of acutely ill patients. If a priming inflammatory stress is followed with 24--48 h later by a provocative event, the final result can be amplified leading to potentially devastating clinical consequences.

The early history of the Shwartzman phenomenon {#sec2-1753425918808008}
==============================================

Gregory Shwartzman (1896--1965) was born in Odessa, Russia, and received his medical degree in Brussels, Belgium. He did his post-doctoral training at the Lister Institute in London. He then immigrated to the United States in 1923 and began his work in bacteriology at the Mt. Sinai Hospital in New York City. He became the director of the Department of Bacteriology in 1926 and made his seminal discovery on what we now call the dermal or local Shwartzman phenomenon over the next 2 yr with his first publication in 1928.^2^

Using sterile culture filtrates of the Gram-negative bacterium *Bacillus* (a.k.a.) *Salmonella typhosus,* he repeatedly demonstrated in several hundred rabbits that an intradermal injection of the culture filtrate as a preparatory injection, followed by a second provocative dose of the same culture filtrate intravenously 24 h later, induced a localized area of severe, hemorrhagic necrosis at the first injection site.^2^ The timing between injections was critical; if the provocative challenge dose was too short (\<2 h) or too long (\>48 h) the dermal reaction did not occur. He noted that the same stereotypical reaction was highly reproducible in most rabbits. However, 22% of the rabbits failed to respond at all and were refractory to each attempt. This was not widely recognized at the time, but this is likely an example of a related phenomenon known as endotoxin tolerance described decades earlier.^3^

Shwartzman experimented with similar preparations with culture filtrates from streptococcal species and failed to duplicate any dermal reactions implicating the primary, but not exclusive, role of Gram-negative cell wall constituents (LPS) to induce the phenomenon. Endotoxin "tolerance" (or more correctly endotoxin "reprogramming") induces many counteracting effects which can block some of the hypersensitivity features displayed in the Shwartzman reaction.^2--6^

Four years before Shwartzman's first publication, an Italian investigator named Giuseppe Sanarelli described similar but more generalized pathological findings in rabbits given a sensitizing dose intravenously, followed by a second provocative intravenous dose of culture filtrates from *Vibrio cholerae*.^6^ These sterile preparations were generated by passing culture supernatants over a submicron filter to trap any remaining viable bacteria.^6,7^ This generalized syndrome of intravascular coagulation and microvascular plugging became known as the generalized Shwartzman-like reaction (or phenomenon). Intravascular clotting was an essential part of the dermal and generalized reaction requiring clotting substrates and adequate amounts of fibrinogen.^8^

The Arthus reaction, endotoxin tolerance, and the Shwartzman phenomenon {#sec3-1753425918808008}
=======================================================================

What initially attracted Dr. Shwartzman's attention, and those of his contemporaries, was that the skin lesions created by this reaction were histologically similar to another recently described reaction call the Arthus phenomenon.^9^ The Arthus reaction was an immune-mediated, hypersensitivity angiitis, involving small arterioles, capillaries, and venules. The lesions showed fibrinoid necrosis with intravascular thrombosis with abundant platelets and granulocytes. Antibody-antigen complexes and complement deposits were readily detectable in the Arthus reaction but not in the Shwartzman reaction.

While Shwartzman's discovery shared many of same histopathologic features, it differed strikingly in several crucial aspects. The Arthus reaction is highly specific with definable Ab complexes, which took weeks to develop and persisted for years. The localized Shwartzman reaction was non-specific, as substituting a second Gram-negative species culture filtrate was sufficient to cause dermal necrosis. The reaction occurred over too short a time for Ab formation and disappeared in a few weeks.^3,7^

Details of cellular immunology of the time did not clearly separate innate immunity from acquired immunity, but chronic immune reactions (lymphocytes), acute phagocytic cellular responses and humoral immunity with Abs and elements of the complement system were reasonably well understood. What Shwartzman had described was something new for endotoxin researchers to study and contrast with the observations of a competing process now referred to as endotoxin tolerance or reprogramming.^10--13^

Endotoxin tolerance was described more than a century ago by Centanni and colleagues during their efforts to use pyrogenic bacterial culture sterile filtrates as therapeutic agents against neoplasms and certain refractory infections.^3,4^ Fever was generated by injections of sterile culture filtrates of *Serratia* spp. and other bacterial filtrates demonstrated some initial therapeutic effects. However, after several therapeutic doses, the pyrogenic filtrates lost the ability to cause fever and the clinical benefits of treatment despite raising the dose 10-fold or more.^3^ Endotoxin tolerance is now appreciated to occur at the transcriptional level where initial pro-inflammatory responses become tolerized over time into a state of systemic inflammatory deactivation, with some preservation anti-microbial defenses. This topic has been recently reviewed.^10--13^

Coley's toxin and the local Shwartzman reaction as an anti-neoplastic therapy {#sec4-1753425918808008}
=============================================================================

In the 1890s, William Coley, a surgical oncologist from New York City, developed what was then called Coley's toxins.^14^ He experimented with this material to induce necrosis and radical cures for patients with advanced malignancies, particularly sarcomas. He and others had had observed that patients with inoperable malignant tumors would occasionally exhibit marked regression of the tumor size if it happened to be in close proximity to an infected site. It was thought that this "collateral damage" to tumors from local inflammation could be harnessed clinically by carefully placing infectious foci adjacent to or inside a neoplastic mass.

He pursued this finding further by using live injections of *Streptococcus pyogenes* from other hospitalized patients with active facial erysipelas. He would inject the bacteria directly into tumors daily for weeks attempting to induce tumor regression. For safety reasons, he later converted to using sterile culture filtrates derived from *S. pyogenes* and the Gram-negative bacillus *Serratia marcescens.* He regularly noted that he would have to increase the dose of toxic combination over time to achieve the desired effect of tumor regression. He called it "second generation" dosing, but he was actually independently confirming the process of endotoxin tolerance.^3^

Coley's limited success with tumor regression was later attributed to the endotoxin found in Coley's toxin, which markedly induced TNF, IL-1, and perhaps other lethal cytokines such as IL-12.^14,15^ Shwartzman himself tried to replicate some of Coley's work by showing that the generalized Shwartzman reaction could elicit hemorrhagic necrosis and regression of transplanted sarcoma tumors in Guinea pigs, rats, and mice.^16^ Further studies into the cellular and molecular mechanisms responsible for the generalized Shwartzman reaction and its opposing effects to endotoxin reprogramming have expanded the understanding of coagulation and innate immune responses to neoplasms, inflammation and thrombosis. These studies continue to the present day (see [Table 1](#table1-1753425918808008){ref-type="table"}).^9--12,17--26^

###### 

Contrasts and comparisons between the generalized Shwartzman-like phenomenon and endotoxin tolerance.

![](10.1177_1753425918808008-table1)

                                                                                           The dermal or generalized Shwartzman-like reaction ("two hit" model)^11--26,56--58,65--68^   Endotoxin tolerance (LPS reprogramming)^11--26,56--58,65--68^
  ---------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- ---------------------------------------------------------------
  Overall effect                                                                           Endotoxin sensitization                                                                      Endotoxin de-sensitization
  Duration of the effect                                                                   Short (\<48 hr)                                                                              Long; Begins within 24 h and lasts for up to 21 d
  Serotype specificity                                                                     None, could substitute other LPS types but not seen with Gram-positive bacteria              None, serotype-independent
  Innate or acquired cellular or humoral immune response                                   Innate immunity and coagulopathy                                                             Innate response driven primarily by myeloid cells
  Need for complement                                                                      Yes                                                                                          No
  Inhibition by heparin or salicylates                                                     No effect                                                                                    No effect
  Requires neutrophils, platelets, and fibrinogen                                          Yes                                                                                          No
  Glucocorticoid pre-treatment allowed a single dose of endotoxin to induce the reaction   Yes                                                                                          No
  TNF, IL-1 or the combination can substitute for endotoxin                                Yes                                                                                          No
  IL-12, IL-15 and/or IFN-γ can substitute for endotoxin                                   Yes                                                                                          No
  Homologous Abs, but not heterogeneous Abs, block reaction                                Yes                                                                                          Unknown

These early studies into immune activators to treat cancer were gradually abandoned as the results were highly variable and often quite toxic. However, the strategy of treating neoplastic diseases with immune adjuvants has recently seen enormous gains in interest with the success of monoclonal antibodies against check-point inhibitors such as PD1.^27^ Patients with previously considered inoperable tumors with little hope have seen some remarkable recoveries by administration of these precise immune T cell activators.

Contributions of the local Shwartzman phenomenon to experimental biology {#sec5-1753425918808008}
========================================================================

Numerous discoveries relating to activators and inhibitors of endotoxin activity were aided by the availability of the simple and reproducibility of the dermal Shwartzman reaction. Intradermal injection of the pro-inflammatory cytokines IL- I and TNF,^15^ and IFN-γ and IL-15 were found to be an effective substitute for the intradermal injection of endotoxin in the local Shwartzman reaction.^15--26^ Exposure to those cytokines in high dose can induce endothelial cells to become thrombogenic and can induce the expression of cell adhesion molecules on endothelial cells, increasing the adherence of leukocytes to the endothelial cells.^28--30^ However, the provocative intravenous injection of LPS can also be substituted by a number of agents, but most of them are not as effective as LPS.

Perhaps the most enduring value of the dermal Shwartzman phenomenon has been its utility as a highly sensitive and specific biomarker for the biochemical and biophysical requirements for endotoxicity. Decades of laboratory investigation into structural immunology of LPS was based upon the dermal Shwartzman reaction as an accurate bio-read out for endotoxin. Through a detailed interrogation of the physiochemical requirements for endotoxicity, the length, number, size and arrangement of the fatty acids that make up lipid A in relationship with MD2 (myeloid differentiation factor 2) and TLR4 was predicted with great accuracy .^31,32^ It was discovered that hexa-acyl, di-phosphorylated disaccharides would be stimulatory agonists, while tetra-acyl, mono-phosphorylated molecules would be antagonists and function as inhibitors of LPS signaling. The final three-dimensional crystal structure of the LPS-MD2-TLR4 now explains many of the predicted structural requirements for full endotoxicity using the dermal Shwartzman as a reliable, *in vivo* guide post.^33^

How did Dr. Sanarelli contribute to the Sanarelli-Shwartzman phenomenon? {#sec6-1753425918808008}
========================================================================

It should be noted that Shwartzman described the localized dermal form of this phenomenon. The generalized Shwartzman-like reaction was actually discovered and initially reported 4 yr earlier in 1924 by the brilliant, but highly controversial, physician-investigator named Giuseppe Sanarelli (1865--1940).^6^ The generalized reaction is sometimes referred to in the literature as the Sanarelli-Shwartzman reaction in honor of the major contributions made to this research effort by Dr. Sanarelli. Sanarelli was an Italian researcher who was a well-trained bacteriologist studying in established microbiology research laboratories in Munich, Germany, and then at the Pasteur institute. He listed Louis Pasteur and Elie Metchnikoff among his mentors. He became an independent investigator in 1895 and accepted an offer to move to Montevideo, Uruguay to establish his own laboratory.

The late 19th century was the pinnacle of the age of the "microbe hunters",^34,35^ and Sanarelli wanted to be part of it. Pasteur had proven the germ theory of disease, and he had demonstrated that attenuation of pathogens in the laboratory made it possible to develop an antiserum or even a vaccine to eliminate many infectious diseases. Many new bacterial pathogens were being discovered and correlated with common infectious diseases of humankind. Koch uncovered evidence that tuberculosis was a transmissible infectious disease in 1882, and is credited with first isolating *Vibrio cholerae* in 1884. He also added much needed clarity and order to the process of establishing claims of new microbial disease causation by following Koch's famous postulates.^35^

By the end of the 1890s, a major, unsolved mystery remained in discovering the possible infectious cause of the highly lethal disease called Yellow Fever. This devastating disease carried a case-fatality rate nearly 33--50%, and still does today. Referred to as the "scourge of the tropics" or "stranger's disease," it often struck new workers and recent arrivals into regions with endemic Yellow Fever. The disease brought headache, confusion, weakness, general malaise, relative bradycardia, often followed by "black vomit" (hematemesis), deep yellowing of the skin (jaundice from liver necrosis), and death.^36^

Yellow Fever epidemics first took hold in the New World as slave workers from Africa began to fill the void of farmers and laborers needed in Central, South, and North America.^37,38^ Young, healthy people were less likely to die from Yellow Fever but no age group was spared. Fortunately, survivors were rendered immune to subsequent infection. Epidemics occurred through the coastal communities from Brazil as far North as Pennsylvania. Outbreaks in Philadelphia (then the US capital) in 1793 and 1798 nearly crippled the young nation\'s administration and intensified the violent partisan conflicts of the day.^38^ Whoever discovered the causative agent of Yellow Fever and its primary mode of transmission would be an instant, international folk hero indeed.

Many theories were postulated to explain the cause of the illness ranging from bad water, miasma theory (airborne mists and contaminated, dirty, living conditions), fomites (particularly bed cloths and linens) mosquitos, fungi, bacteria, or tiny filterable agents.^38--40^ Filterable agents were recognized at the time as viruses that could pass through a submicron filter that would effectively trap almost all bacteria expressing a cell wall.

The race to discover the cause of Yellow Fever was on. This open and quite public challenge pitted South and Central American physician-scientists against each other and a number of European investigators interesting in expanding their influence and prestige within each host countries' respective empires.^37^ Even the US military took an interest as Yellow Fever was a major non-combat killer of soldiers in the Spanish-American War (1898--1900). Yellow Fever was also a formidable impediment to American designs to finish building the Panama Canal after the French had abandoned the effort 20 yr earlier.^38^ The race to discover the cause of Yellow Fever attracted much of the public's imagination and their attention.

Sanarelli was a bacteriologist at heart but his first major contribution to science was correctly recognizing the viral cause of an entirely new neoplastic disease first detected in imported European rabbits into South America in 1896. Rabbits were the favored laboratory animals for raising antisera by microbiologists, including Sanarelli's own laboratory. He was disturbed to find that imported rabbits quickly succumbed to this new illness, which was contagious in European rabbits but not in the local, tropical rabbits found in South America.^41^

He also recognized that European rabbits housed in cages in the outdoors rapidly developed the disease while indoor rabbits caged inside were largely spared from the disease. He correctly speculated that outdoor rabbits would be exposed to mosquitos and this must be the way the lethal disease was transmitted. Autopsies revealed the disease to manifest as multiple tumors in multiple organs and he called the disease myxomatosis.^41^ He discovered it was caused by a filterable agent, later to be confirmed as an oncogenic, lethal poxvirus. Local strains of rabbits were apparently immune, while imported rabbits were highly susceptible.^41--43^ This same virus was later used in Australia as an abortive attempt to biologically control the massive populations of European rabbits that arose after their introduction into Australia.^44^ Sanarelli was widely and rightfully acknowledged as a gifted microbiologist for this major discovery. He then set out to find the microbial cause of Yellow Fever.

In 1897, he mistakenly announced that he had found the bacterial cause of Yellow Fever in the blood of its victims.^40^ He also announced that he had developed a curative intra-venous antiserum that he considered "tellement simple et tellement sur" (so simple and so safe). His claim was immediately taken seriously as he was a respected microbiologist, competent in the latest techniques of sterility and familiar with careful scientific methods. He called the pathogen *Bacillus icteroides.* He then sought to prove Koch's postulates and he appropriately shared his pathogen and his data with other competing laboratories. He even designed clinical trials to test an antiserum he had developed to defend against his newly discovered, causative bacterium. Other laboratories tried to replicate his results with mixed and contradictory results, and began to question the validity of his claims.^40,45,46^

Around this time, the Yellow Fever Commission from the US showed up to try to bring some order to the chaotic situation.^38,47^ General George Sternberg reviewed the Sanarelli data and found fault in his methods, sterile technique, and the analytic methods used in his early clinical trials with antisera. Within 2 yr the American mission under the capable command of Walter Reed, and with assistance from a Cuban investigator named Carlos Finlay, confirmed that Yellow Fever was a mosquito-borne, viral disease transmitted by *Aedes aegypti* (previously called *Stegamyia faciens*) in 1900.^48^ Sanarelli probably misinterpreted his own data and the pathogen he thought caused Yellow Fever was likely a contaminating strain of *Salmonella*spp. known as *S. cholerae suis* that causes hog cholera.^48,49^

Sanarelli compounded his difficulties by trying to convince others he had discovered a bacterial cause of Yellow Fever. He injected his bacterial pathogen intravenously to cause disease in uninformed, human "volunteers," and then proceeded to attempt to rescue them with his experimental anti-serum.^49^ Details are sketchy but some of these participants were likely prisoners from a nearby institutional outbreak of suspected Yellow Fever. As Dr. Sanarelli noted, the prison epidemic was "un hasard vraiment heureux" (a stroke of good luck) for acquiring study subjects for his human experiments.^40,49^ Apparently, three of the first five study subjects reportedly died from the experiment. This fiasco did, in fact, demonstrate that Sanarelli had discovered a potentially lethal, bloodstream, bacterial pathogen, but it was not the cause of Yellow Fever.

This rather callous human experiment dismayed the medical community and tarnished the reputation of Dr. Sanarelli. No formal international standards for human subjects in medical experimentation existed at the time and the Nuremburg trials of Nazi doctors and the Helsinki accords were more than a half century away.^50,51^ Nonetheless, Sanarelli was roundly criticized by anti-vivisectionists and his fellow researchers as well. Sir William Osler is reported to have said publically, "To deliberately inject a poison of known high degree of virulency into a human being, unless you obtain that man's sanction, is not ridiculous, it's criminal".^51^

It should be noted that a generally accepted code of medical ethics for human experimentation did not exist in the 18th and 19th centuries. Edward Jenner performed probably the most important medical experiment in history by demonstrating that vaccinia (cowpox) from the hands of milk maids, if delivered by skin incisions in young children, could protect against variola infection (small pox).^52^ These were uncontrolled experiments done in children, without any evidence of written consent, and followed by actual smallpox virus challenge inoculations. Fortunately, the experiment was successful, and the rest is history. Risky medical experiments, without proper informed consent, continued to be performed on vulnerable subjects such as convicted prisoners and mentally impaired patients in the US up until the mid-1900s---a practice now universally considered unacceptable.^53,54^

Partly in response to this medical research scandal, the Walter Reed commission went to great lengths to provide a detailed, well written, informed consent for all human experiments needed to determine the cause and method of transmissibility of Yellow Fever.^46--48^ They followed an egalitarian ethos prevalent at the time that championed the idea; "Before you perform experiments on human subjects, you should be willing to perform the same experiment on yourself first." The four lead investigators of the Yellow Fever commission were Walter Reed, James Carroll, Jesse Lazear, and Aristides Agramonte. Dr. Agramonte had already survived Yellow Fever years earlier and was thus immune to reinfection. Carroll allowed infected mosquitos to feed upon his exposed skin. Within a week he was deathly ill but survived. Lazear was next to roll up his sleeve to infected mosquitos and promptly died from the experiment. Walter Reed wisely elected to halt further testing on fellow researchers who had sacrificed enough.^48^

Sanarelli never fully recovered from his misadventures with finding the elusive Yellow Fever pathogen.^49^ He spent the rest of his career working on the pathogenesis of *Vibrio cholerae* in experimental animals.^56^ Through a detailed and careful set of timed experiments, he proved that endotoxin-laden, culture filtrates from *V. cholerae* could cause a thrombotic diathesis both locally within nutrient blood vessels within the gastrointestinal tract, and systemically in distant organs such as the kidney and spleen. He could reproduce intravascular clotting of mesenteric blood vessels using culture filtrates given intravenously if separated by 24 hr. This effect was independent of the well-known, diarrhea-causing cholera exotoxin.

Importantly, he showed that the same dose of live bacteria vs. killed bacterial intravenous injections of *Vibrio cholerae* was equally lethal in the rabbit model. This was early evidence of the critical role of endotoxin in the pathogenesis of enteric Gram-negative bacterial infections. He published his work in a series of papers from 1919 to 1924.^6,55^ These histopathologic findings from the Sanarelli laboratory were notable for their similarities with the localized dermal reaction observed by Shwartzman a few years later in the late 1920s. The combined discoveries are now often referred to simply as the Shwartzman phenomenon or, perhaps more correctly, the Sanarelli-Shwartzman phenomenon.

Surprisingly, neither man referenced the other investigator's work in their initial study reports. It does not appear that they ever actively collaborated with each other in their laboratory projects. It is possible, perhaps even likely, that they never met. Sanarelli's laboratory work was done in Uruguay and in Europe, and he was 31 yr older than Shwartzman. Sanarelli published most of his work in French, but also in the German and the Italian scientific literature. His most important primary publications were all published in French in the *Annales d' Institut Pasteur*.^55^

Pathophysiology of the Shwartzman-like reaction {#sec7-1753425918808008}
===============================================

The generalized Shwartzman reaction is created in experimental animals by injecting two, carefully spaced, sublethal doses of endotoxin. The time interval required between first (preparatory) and second (provocative) dose is usually between 2 and 48 hr. The reaction manifests intravascular "hyaline" or \"fibrinoid" deposits, which are immuno-chemically identical to fibrin.^56^ The reaction carried out *in vivo* causes deposition of fibrin in kidneys, liver, spleen, and lungs as well.^57^ The fibrin deposits gradually disappear from all these organs except the kidneys, which appears after the second (provocative) dose in generalized Shwartzman reaction. Those deposits are not only a result of blood clotting and intravascular blood clotting, but also of inhibition of fibrinolysis.^58^ This and other variants of the "two hit" model of sepsis are currently in widespread use in research laboratories around the globe, but are seldom referred to as the Shwartzman reaction in the current literature.^60,61^

Studies of sepsis in humans and other species consistently reveal that innate immune activation and disturbances in coagulation to be inseparably linked, with each acting as positive feedback for activation of the other.^59,60^ Evidence of diffuse coagulation activity with thrombocytopenia is highly predictive of mortality in sepsis.^61,62^ Activation of the coagulation system is thought to be the primary event that triggers Shwartzman phenomenon, leading to a consumptive coagulopathy of the microvasculature, which can be localized or generalized, acute, subacute, or chronic. Intravascular coagulation activation likely contributes to multisystem organ dysfunction syndrome (MODS).^63,64^

Necrotizing hemorrhagic tissue reaction is the hallmark of the Shwartzman-like reaction. Microthrombi composed of platelets and leukocytes accumulate in the vessels after the exposure to endotoxins. The Shwartzman reaction depends on integrity of the clotting system, on platelets and on polymorphonuclear leukocytes, and the complement system.^19--23^ Intravascular activation of complement triggers the release of anaphylatoxins such as C3a and C5a into the circulation seem to play a major role in the propagation of Shwartzman reaction. The cleavage products activate neutrophils and platelets, causing them to aggregate and adhere to vascular endothelium. This results in the occlusion of small vessels and release toxic mediators.^14,21,64^ In practice, local and generalized Shwartzman reactions are models of thrombo-hemorrhagic skin necrosis and DIC, respectively.

The robustness of the immune response, and the number of circulating leukocytes at the time of preparing (i.e., the first dose of toxin) and provoking (i.e., the second dose of toxin) seem to have a significant impact on the development of generalized Shwartzman reaction. A study by Dr. Lewis Thomas found that the generalized Shwartzman reaction, produced by two injections of meningococcal toxin in rabbits, was aggravated by the administration of cortisone and corticotropin (ACTH).^19--21^ In contrast, when leukopenia was produced before the preparing injection of toxin (using treatment with nitrogen mustard) the generalized Shwartzman reaction was inhibited.^21^ However, when the femoral bone marrow was shielded from the action of nitrogen mustard and leukopenia was prevented, no inhibition of the generalized Shwartzman phenomenon was demonstrable. A summary of the advances in understanding the interactions between the coagulation system and innate immunity, differences between endotoxin priming and endotoxin tolerance are listed in [Table 1](#table1-1753425918808008){ref-type="table"}.^11--26,65--67^

Univisceral Shwartzman-like reaction {#sec8-1753425918808008}
====================================

Local Shwartzman reaction can be induced many different tissues and is not limited to the skin.^68,69^ The reaction can be induced in the lung by repetitive intratracheal administration of an inoculum.^70^ Acute hepatic necrosis can also be produced by a local Shwartzman-like reaction. The locality of this reaction is related to its "univiscerality", where only a single organ is targeted.^70,71^ For that reason, a distinct type of Shwartzman-like reaction, called "Univisceral Shwartzman Reaction", has been proposed. Much of the organ damage accompanied by sepsis, such as acute liver necrosis, Waterhouse-Friderichsen\'s syndrome,^71^ hemolytic-uremic syndrome, idiopathic pulmonary hemorrhage, acute pancreatitis, acute pituitary necrosis, and pseudomembranous colitis^72,73^ all seem to have features suggestive of this type of single, organ-specific, Shwartzman-like reaction with focal intravascular coagulation.^74^

Ischemia, although a major contributor to the development of the dermal Shwartzman reaction, might not be the primary cause of the phenomenon. A study to determine the baseline sensitivity of rat skin to ischemia, showed that a period of ischemia was insufficient to cause necrosis. The study suggested that the bacterial infection can sensitize tissues to the effects of ischemia, effectively lowering the threshold to acquiring irreversible cell injury (see [Table 2](#table2-1753425918808008){ref-type="table"}).^75^

###### 

Clinical presentation and mediators of univisceral and general Shwartzman reaction.

![](10.1177_1753425918808008-table2)

                 Organs involved                                                                                                                          Clinical presentation                                                                                                                                                                                                                 Mediators^69--75^
  -------------- ---------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Dermal         Skin                                                                                                                                     Skin purpura                                                                                                                                                                                                                          Intradermal LPS, IL-1, IFN-γ, and TNF
  Uni-visceral   One of the following:Lung, liver, kidney, pancreas, colon, pituitary, or adrenal gland                                                   Single organ failure or dysfunction:- Acute liver necrosis- Waterhouse-Friderichsen\'s syndrome- Hemolytic Uremic Syndrome- Idiopathic pulmonary hemorrhage- Acute pancreatitis- Acute pituitary necrosis- Pseudomembranous colitis   Intratracheal or IV endotoxin administrationHepatotoxins, hepatitisDIC, adrenal apoplexyEnterohemorrhagic *Escherichia coli*Unknown, possibly toxinsChemical or ductal obstructionSevere obstetrical hemorrhage*Clostridium difficile*
  Generalized    Two or more of the following: Lung, liver, kidney, pancreas, colon, pituitary, or adrenal gland, bone marrow, blood cells, conjunctiva   MODSDICHUSTTP*Purpura fulminans*                                                                                                                                                                                                      IV administration of endotoxinSeptic shockEnterohemorrhagic *E. coli*ADAMTS 13 auto-AbMeningococcemia

HUS: Hemolytic uremic syndrome; MODS multi-organ dysfunction syndrome; DIC disseminated intravascular coagulation; TTP: thrombotic thrombocytopenic purpura

The "two-hit" experimental model of sepsis, DIC, and netosis {#sec9-1753425918808008}
============================================================

The two-hit experimental model of sepsis is a variant of the generalized Shwartzman-like reaction and is accompanied by pronounced changes in blood clotting and fibrinolytic systems. In addition, circulating neutrophils were found to rapidly decrease shortly after injection, along with a significant decrease in circulating platelets. The margination of neutrophils in the pulmonary vasculature accounted for most of the trapped neutrophils.^76,77^ Netosis, the intravascular generation of neutrophil extracellular traps (NETs), likely contributes to accumulations of platelets and neutrophils within the microcirculation.^62,77^ Micro-particles released from damaged endothelial cells and myeloid cells further accelerate the pro-coagulant and proinflammatory actions of intravascular thrombin generation.^59--61^ Thrombin generation, activated factor X and tissue factor (TF): FVIIa complexes are all highly inflammatory events via activation of the four human protease activated receptors (PAR) expressed on endothelial cell surfaces (see [Figure 2](#fig2-1753425918808008){ref-type="fig"}).^62--64^

Ample evidence now exists that demonstrates a wide-ranging cross-talk between hemostasis and inflammation, which is likely implicated in the pathogenesis of organ dysfunction in patients with sepsis.^64^ The generalized phenomenon involves disseminated intravascular coagulation (DIC) beginning with upregulation of the TF pathway of hemostasis via endothelial TF exposure to circulating factor VII. The TF: FVIIa complex initiates the TF pathway of clotting. Concomitantly, platelets are activated when surface receptor glycoprotein Ibα encounters excess levels of high molecular mass von-Willebrand Factor polymerized under conditions of shear stress to exposed collagen fibers. Coagulation abnormalities are nearly universal in septic patients and is a key contributor to the development of multiple organ failure.^61,62^ Fibrin deposition is not cleared efficiently and it precipitates and remains within vessels (see [Figure 1a and b](#fig1-1753425918808008){ref-type="fig"}).^78,79^

![(a) Skin biopsy (20×) showing evidence of dermal necrosis from small vessel obstruction from deposition of fibrinoid material, platelets, and nuclear debris within the capillary lumen in a patient with acute meningococcemia. The black arrows highlight areas of tissue necrosis surrounding obstructed blood vessels. The white arrow shows occluded vessels with fibrinoid material, neutrophil remnants and platelets. (b) Skin biopsy of the same patient at higher magnification (40×); the black arrow shows thrombosis in capillaries with RBCs clogging the vessel lumen; the white arrow shows a damaged vessel wall with swollen endothelial cells with white blood cells and platelets along the vessel lumen with evidence of extravasation of RBCs and dermal necrosis. Histopathology slides are provided courtesy of Gladys Telang.](10.1177_1753425918808008-fig1){#fig1-1753425918808008}

Fulminant DIC presents in severe sepsis and is manifested in both thrombosis and diffuse hemorrhage. Initiation of coagulation activation and consequent thrombin generation is now believed to be caused by expression of TF on activated monocytes and endothelial cells. This reaction is at a level where it become ineffectually offset by TF pathway inhibitor. At the same time, the protein C system and other endothelial-associated anticoagulant pathways are impaired by pro-inflammatory cytokines.^79^ In addition, the removal of fibrin is hindered by inactivation of the endogenous fibrinolytic system. Increased fibrin generation, coupled with its impaired breakdown, lead to deposition of microvascular clots in dermal vessels and throughout the body.^78,79^

The most clinically relevant syndrome in which the generalized Shwartzman-like reaction appears to play a central role is purpura fulminans. The similarities between the generalized Shwartzman reaction and *purpura fulminans* in septic patients were commented upon by Shwartzman and his colleagues in their later writings.^80,81^ These findings which lead them to speculate that similar underlying molecular mechanisms were responsible for the tissue injury.^80^

The dermal Shwartzman reaction is histologically indistinguishable from hemorrhagic necrosis of the skin seen in some patients with meningococcemia and septic shock.^82,83^ Pathologic and massive activation of coagulation followed by diffuse formation of micro-thrombus formation which can coalesce into patches of dermal necrosis. *Purpura fulminans* is a tragic clinico-pathologic syndrome that proceeds at a frightening pace in previously healthy children or young adults. Fatalities can result in as little as 24 hr from onset of symptoms. The histopathologic similarities between *purpura fulminans* and the dermal Shwartzman phenomenon suggest that *purpura fulminans* may be the closest clinical illness to what Shwartzman initially described experimentally in 1928.^2^

While *purpura fulminans* is occasionally seen with other Gram-negative bacterial pathogens, *Neisseria meningitidis* is the principal causative microorganism. The mechanisms underlying this well-known association between meningococcemia and overt tissue thrombosis and skin necrosis is now becoming better understood (see [Figure 2](#fig2-1753425918808008){ref-type="fig"}). Greater adherence of its meningococcal LOS is found in the outer membrane, which has a greater ratio of lipid A content versus polysaccharide content found than most bloodstream enteric Gram-negative pathogens.^82^ Experimentally, the LOS of meningococci resembles rough LPS found in some enteric Gram-negative bacteria, which are incompletely linked to long polysaccharide side chains. The LOS of meningococci are 5--10 times more potent in the dermal Shwartzman reaction but are not more potent in mouse lethality assays.^82^

![The generalized Shwartzman-like phenomenon during meningococcemia.^77,79,82--85^ Induction of ADAM-10 cleaves EPCR, impairs APC formation, and leads to purpura fulminans. TJ: Tight junctions; EC: endothelial cells; ECM: extracellular matrix; TFPI: tissue factor pathway inhibitor; AT3/HS: anti-thrombin 3/heparan sulfate; EPCR: endothelial protein C receptor; ADAM-10: a disintegrin and metalloprotease-10; PC: protein C; APC: Activated Protein C; P-sel: P-selectin; Nm: *Neisseria meningitidis*; PSGL-1: P-selectin glycoprotein ligand-1; PMNs: polymorphonuclear cells; TF: tissue factor; F: factor; PT: prothrombin; Tb: thrombin; FBN: fibrinogen; MD2: myeloid differentiation factor 2; VWF: von Willebrand's factor; PAR-1: Protease activated receptor-1; NETs: neutrophil extracellular traps; mt DNA: mitochondrial DNA.](10.1177_1753425918808008-fig2){#fig2-1753425918808008}

Meningococcal invasion of the bloodstream leads to binding of the pathogen to the apical surface of endothelial cells within the microcirculation via their type IV pili.^83,84^ This event induces endothelial cells to generate a shedding enzyme called ADAM-10 (a disintegrin and metalloprotease-10), which cleaves the endothelial protein C receptor (EPCR).^84,85^ This results in the loss of a major feedback inhibitor of ongoing coagulation and endothelial cell damage known as Activated Protein C (APC).^79,85^ The generation of APC occurs when the circulating zymogen Protein C is activated by partial proteolysis by thrombin: thrombomodulin complexes. APC is the major inhibitor of intravascular clotting by degradation of the two acceleration factors of the coagulation system FVa and FVIIIa. EPCR: APC complexes on the endothelial cell surface also activate the cytoprotective effects of APC. Both these control mechanisms are lost when meningococci invade and induce EPCR shedding.^84,85^

Infants born with congenital defects in the Protein C pathway rapidly develop *purpura fulminans* within the first few days of life that closely resembles the clinical and pathologic findings in meningococcal *purpura fulminans*.^86^ Early treatment in these infants with protein C concentrate will prevent ongoing thrombosis and tissue necrosis testifying to the central role of the Protein C pathway deficiency in these syndromes.

While clinical or autopsy evidence of systemic microthrombi or dermal necrosis is quite rare in patients with septic shock today,^64^ biochemical evidence of systemic coagulation activation and platelet activation is almost uniformly present.^59--64^ The magnitude of coagulation abnormalities is directly correlated with increasing hospital mortality rates in septic patients.^59,61,79,87^ A recent nation-wide registry in Japan found that early treatment with systemic anticoagulation significantly improved overall hospital mortality rates in patients with infection-related disseminated intravascular coagulation.^88^ Similar findings have been reported in large clinical cohort studies in the US, where the severity of coagulopathy was directly linked to hospital mortality.^87^ Clinical trials with a recombinant human form of soluble thrombomodulin can restore and regulate the APC pathway in sepsis-associated DIC. This regulatory protein or similar proteins might provide a new treatment strategy for sepsis-induced coagulopathy.^88,89^

Summary and conclusions {#sec10-1753425918808008}
=======================

The discovery of the Sanarelli-Shwartzman phenomenon has taught us a great deal about the interactions between coagulation and inflammation, endotoxin priming and tolerance, and the endothelial membrane interface with clotting and innate immune signaling. The combined effects on the coagulopathy, vasculopathy and immunopathy of septic shock is beginning to take shape. Hopefully, this knowledge will translate into improved treatments to manage sepsis and other inflammatory states.^90^

Elements of the Shwartzman-like reaction will continue to be useful in the study of two-hit models of sepsis in the animal laboratory. Hopefully, insights provided in the laboratory will benefit in the care of complicated patients who have sustained multiple physiologic insults from infection, trauma, immune compromised states, and various hypoperfusion states such as prolonged septic shock. Moreover, the dermal Shwartzman reaction may yet prove useful in investigations into the molecular explanation for human cases of *purpura fulminans* from unusual environmental bacterial infections from such pathogens such as *Aeromonas*, *Vibrio*, or *Capnocytophaga* spp. (see [Table 3](#table3-1753425918808008){ref-type="table"}).^91--104^

###### 

Pathogens associated with generalized Shwartzman-like reaction with sepsis-induced *purpura fulminans*.

![](10.1177_1753425918808008-table3)

  Pathogen                                                                     Primary pathogen-inducing factor(s)                          Important host factors
  ---------------------------------------------------------------------------- ------------------------------------------------------------ ----------------------------------------------------------------------------------
  *Neisseria meningitidis* ^82--84^                                            LOS, induce EPCR shedding enzyme                             Lack of protective Abs, Complement deficiency, asplenia
  *Vibrio vulnificus,* other *Vibrio* spp.^91--94^                             Possible role of cytotoxins                                  Exposure to salt water through open wounds, liver disease, immune compromise
  *Aeromonas hydrophilia* ^95,96^                                              Unknown                                                      Exposure to fresh water or brackish water through open wounds, immune compromise
  *Staphylococcus aureus* ^97^                                                 Superantigens, cytotoxins                                    Immune compromise
  *Streptococcus pyogenes* ^98^                                                Protective capsules                                          Lack of protective Abs, asplenia
  *Streptococcus pneumoniae* ^99^                                              Protective capsules                                          Asplenia, lack of protective Abs
  *Haemophilus influenzae* ^98^                                                Protective capsules                                          Lack of protective Abs, asplenia
  *Capnocytophaga canimorsus* ^100^                                            Unknown                                                      Asplenia, dog bites, immune compromise
  *Escherichia coli* ^101,102^                                                 Possible cytotoxic necrotoxic factors, virulence plasmids    Unknown
  *Bacillus anthracis* ^103^                                                   Lethal toxin and edema toxin                                 Unknown
  Israeli spotted fever (*Rickettsia conorii* subspecies *israelensis*)^104^   Unknown but this sub-species carries a high mortality rate   Exposure to infected tick vector

Like most disciplines in scientific inquiry, attempts at understanding the basic nature of human host response to infection have had its share of miscues, false leads, failed hypotheses, and tragic mistakes.^105,106^ The pace of discovery is quickening as technologic advances in molecular biology keep churning out new challenges to established ideas and longstanding hypotheses. No matter how compelling the experimental evidence, mistakes will be made when trying to bring new ideas from the bench to the bedside. We need to realize and accept the fact that new research studies involving human subjects and vulnerable patients will inevitably carry some intrinsic risk. Fortunately, the mistakes, ethical blunders, and sometimes egregious human errors made while conducting clinical trials in the 19th and 20th century will serve as an ethical guide for biomedical research in the present and future. We owe it to our patients to live up to the high standards placed upon us and expected from us.
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